Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Short-term Investments (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Short-term Investments for 5 consecutive years, with $128.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments rose 260.13% year-over-year to $128.6 million, compared with a TTM value of $128.6 million through Dec 2025, up 260.13%, and an annual FY2025 reading of $128.6 million, up 260.13% over the prior year.
  • Short-term Investments was $128.6 million for Q4 2025 at Zevra Therapeutics, down from $145.1 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $154.9 million in Q2 2025 and bottomed at $9.9 million in Q1 2024.
  • Average Short-term Investments over 4 years is $58.6 million, with a median of $30.3 million recorded in 2024.
  • The sharpest move saw Short-term Investments surged 44.65% in 2024, then soared 1449.3% in 2025.
  • Year by year, Short-term Investments stood at $16.9 million in 2022, then skyrocketed by 46.08% to $24.7 million in 2023, then surged by 44.65% to $35.7 million in 2024, then skyrocketed by 260.13% to $128.6 million in 2025.
  • Business Quant data shows Short-term Investments for ZVRA at $128.6 million in Q4 2025, $145.1 million in Q3 2025, and $154.9 million in Q2 2025.